Insider Selling: Boston Scientific (NYSE:BSX) EVP Sells $4,923,500.00 in Stock

Boston Scientific Corporation (NYSE:BSX) EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Joseph Michael Fitzgerald also recently made the following trade(s):

• On Tuesday, September 2nd, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00.
• On Friday, August 1st, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00.

Boston Scientific Stock Performance

NYSE BSX opened at $97.30 on Friday. The stock has a market capitalization of $144.17 billion, a price-to-earnings ratio of 57.91, a PEG ratio of 2.32 and a beta of 0.61. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average of $102.93 and a 200 day moving average of $102.05.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Institutional Trading of Boston Scientific

Several hedge funds have recently modified their holdings of BSX. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. NBC Securities Inc. raised its stake in Boston Scientific by 110,136.4% in the first quarter. NBC Securities Inc. now owns 12,126 shares of the medical equipment provider’s stock valued at $1,223,000 after buying an additional 12,115 shares in the last quarter. Harbor Investment Advisory LLC raised its stake in Boston Scientific by 57.5% in the first quarter. Harbor Investment Advisory LLC now owns 9,385 shares of the medical equipment provider’s stock valued at $947,000 after buying an additional 3,428 shares in the last quarter. Merit Financial Group LLC raised its stake in Boston Scientific by 12.0% in the first quarter. Merit Financial Group LLC now owns 120,420 shares of the medical equipment provider’s stock valued at $12,148,000 after buying an additional 12,938 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Boston Scientific by 7.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 114,840 shares of the medical equipment provider’s stock valued at $11,585,000 after buying an additional 7,500 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on BSX. BTIG Research upped their price target on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Wells Fargo & Company increased their target price on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. Finally, Canaccord Genuity Group increased their target price on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $120.79.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.